Roth Capital Issues Optimistic Outlook for Clene Earnings

Clene Inc. (NASDAQ:CLNN) – Equities research analysts at Roth Capital increased their Q2 2025 earnings per share (EPS) estimates for shares of Clene in a report issued on Wednesday, May 7th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.58) per share for the quarter, up from their previous forecast of ($0.92). The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. Roth Capital also issued estimates for Clene’s Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.44) EPS, FY2025 earnings at ($2.36) EPS, FY2026 earnings at ($1.45) EPS, FY2027 earnings at $6.22 EPS, FY2028 earnings at $7.87 EPS and FY2029 earnings at $11.04 EPS.

Other equities analysts also recently issued reports about the company. Benchmark dropped their target price on Clene from $84.00 to $33.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. HC Wainwright reaffirmed a “buy” rating and set a $31.00 target price on shares of Clene in a research note on Tuesday, April 8th. D. Boral Capital restated a “buy” rating and set a $23.00 price objective on shares of Clene in a report on Thursday, May 8th. Finally, Jones Trading assumed coverage on Clene in a research report on Wednesday, April 23rd. They set a “buy” rating and a $30.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $40.00.

Clene Trading Up 3.4%

Clene stock opened at $2.72 on Monday. The company has a market capitalization of $24.43 million, a PE ratio of -0.52 and a beta of 0.46. Clene has a 12 month low of $2.55 and a 12 month high of $9.20. The stock has a 50-day moving average price of $3.33 and a two-hundred day moving average price of $4.29.

Clene (NASDAQ:CLNN) last posted its earnings results on Wednesday, May 7th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.60. The firm had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.07 million. Clene had a negative return on equity of 1,106.30% and a negative net margin of 8,556.77%.

Institutional Trading of Clene

Several hedge funds have recently made changes to their positions in the company. Penn Davis Mcfarland Inc. bought a new stake in shares of Clene in the first quarter valued at $34,000. Fullcircle Wealth LLC bought a new position in Clene in the 4th quarter worth about $69,000. Renaissance Technologies LLC bought a new position in Clene in the 4th quarter worth about $96,000. Geode Capital Management LLC increased its stake in Clene by 52.9% in the 4th quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock worth $346,000 after acquiring an additional 22,539 shares during the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of Clene during the 4th quarter valued at about $69,000. 23.28% of the stock is currently owned by institutional investors.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.